Approved based on the phase 3 OCARINA II trial, the new subcutaneous formulation offers patients with multiple sclerosis more flexibility to choose treatment options that suit their individual needs.

A recent study showed that an increase in anti-hepatitis E virus seroprevalence in patients with chronic inflammatory demyelinating polyneuropathy was not a consequence of intravenous immunoglobulin therapy.

VO659 was considered safe and well tolerated, with treated patients showing no sustained increase in neurofilament light protein through day 85 of treatment.

New findings from the CAMPSIITE trial highlight that RGX-121 gene therapy significantly reduces cerebrospinal fluid biomarkers, suggesting its potential as a first treatment for Hunter syndrome.

BB-031 aims to expand the population eligible for acute revascularization therapy by reopening blocked arteries beyond the traditional therapeutic window, potentially increasing eligible AIS patients by nearly 50%.

Results revealed that adjunctive treatment with intravenous argatroban or eptifibatide was associated with increased mortality in acute ischemic stroke treated with intravenous thrombolysis.

Treatment with Lu AG09222 as a migraine preventive was safe, with common adverse events that included COVID-19, nasopharyngitis, and fatigue.

Michael McDermott, MD, chief medical executive of Baptist Health Miami Neuroscience Institute, provided commentary on the early stages of a recently designed protective surfing helmet.

Across 4 trials with over 4800 patients, rimegepant demonstrated superior pain and symptom relief 2 hours post-dose, with fewer requiring rescue medication.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

The postdoctoral researcher at Amsterdam University Medical Center talked about a tool that helps assess the likelihood of transitioning to secondary progressive multiple sclerosis, allowing clinicians to make informed treatment decisions in a timely manner.

Radiprodil, a novel NMDA receptor modulator, demonstrated significant potential in reducing seizure frequency, with 71% of patients showing at least a 50% reduction in motor seizures.

Catch up on any of the neurology news headlines you may have missed over the course of August 2024, compiled all into one place by the NeurologyLive® team.

Lennox-Gastaut syndrome took an average of 12.3 months to be diagnosed after the first seizure, often leading to delays in treatment.

The agency’s letter of support for using the α-synuclein seed amplification assay biomarker was supported by data observed in the Parkinson's Progression Markers Initiative cohort study.

Representatives from the SCN8A Alliance provided clinical insight on a recently published paper that captured information on the estimated frequency, severity, and prognosis of comorbidities in SCN8A-related disorder phenotypes. [WATCH TIME: 5 minutes]

Recent findings from a phase 3 study revealed improvements in independent ambulation and overall functional outcomes in patients with large hemispheric infarction treated with intravenous glibenclamide.

VES001 demonstrated safety, strong target engagement, and normalization of progranulin levels in healthy volunteers, advancing toward a phase 2a trial.

Here's some of what is coming soon to NeurologyLive® this week.

CT-132, a digital therapy, targets brain hypersensitivity and provided non-pharmacological treatment, showing promise for integration into migraine management.

Ashwini Sharan, MD, chief medical officer of Medtronic Neuromodulation, provided commentary on the FDA’s decision to approve asleep deep brain stimulation for the treatment of Parkinson disease and essential tremor.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on essential tremor.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 6, 2024.

Treatment with DYNE-251 revealed dose dependent exon skipping and dystrophin expression as well as improvement in multiple functional end points in both cohorts of the phase 1/2 DELIVER trial.